Monthly Archives: March 2014

UC Merced Anchor Cats: Inside The Lab (Stem Cells) – Video

Posted: March 15, 2014 at 6:45 am


UC Merced Anchor Cats: Inside The Lab (Stem Cells)
Anchor Cat Andrea Cho interviews Anley "T" Tefera, Graduate Researcher. *Produced By Students First Center in partnership with Media Cats For ALL Anchor Cats...

By: UC Merced Students First Center

Originally posted here:
UC Merced Anchor Cats: Inside The Lab (Stem Cells) - Video

Posted in Stem Cell Videos | Comments Off on UC Merced Anchor Cats: Inside The Lab (Stem Cells) – Video

fat stem cells 2 – Video

Posted: March 15, 2014 at 6:45 am


fat stem cells 2
http://www.arthritistreatmentcenter.com Stem Cells | What about fat? Farshid Guilak and colleagues published an article in the journal Biorheology. In it the...

By: Nathan Wei

More here:
fat stem cells 2 - Video

Posted in Stem Cell Videos | Comments Off on fat stem cells 2 – Video

Structural biology, Proteomics & Cancer Symposium: 07 Cancer Program of VNU – Video

Posted: March 15, 2014 at 6:44 am


Structural biology, Proteomics Cancer Symposium: 07 Cancer Program of VNU
Cancer Program of VNU-Dr. Pham Van Phuc Deputy-Head, Laboratory of Stem Cell Research and Application, HCMUS, VNU-HCM, VN Structural biology, Proteomics Ca...

By: Stem Cell Lab HCMUS

Read more:
Structural biology, Proteomics & Cancer Symposium: 07 Cancer Program of VNU - Video

Posted in Stem Cell Research | Comments Off on Structural biology, Proteomics & Cancer Symposium: 07 Cancer Program of VNU – Video

Lekha & Varun – Why they chose to preserve their baby's stem cells – Video

Posted: March 14, 2014 at 10:46 pm


Lekha Varun - Why they chose to preserve their baby #39;s stem cells
Lekha Varun, young parents from Chennai talk about why they thought it was important to preserve their baby #39;s stem cells. For further information on stem c...

By: Mylifecell

Go here to see the original:
Lekha & Varun - Why they chose to preserve their baby's stem cells - Video

Posted in Stem Cells | Comments Off on Lekha & Varun – Why they chose to preserve their baby's stem cells – Video

Controversy Around Stem Cell Discovery May Lead To Retraction

Posted: March 14, 2014 at 10:45 pm

March 14, 2014

Lee Rannals for redOrbit.com Your Universe Online

Japanese scientists who in January announced they developed a new method to create stem cells using blood cells and acid are considering retracting their study.

Scientists from the RIKEN Center for Developmental Biology in Kobe, Japan announced earlier this year that they had discovered that dipping blood cells into acid could turn them into stem cells. This study was considered ground-breaking research in the field, but now the scientists are not so sure of their findings.

The team initially discovered the method in mice, finding that by simply exposing blood cells to acidic liquids, they would turn into stimulus-triggered acquisition of pluripotency cells (STAP cells). They found that white blood cells in newborn mice were returned to a versatile state through the simple process. Creating stem cells in a lab this way would help grow cells to replenish organs damaged by disease or accident.

However, after the announcement of this discovery scientists from all over the world criticized the research because they could not repeat the method to create these cells. Other critics said photographs and sentences in the report were identical to those used in earlier theses.

RIKEN said it is establishing a third-party panel to investigate the content of the report and is planning to withdraw the claim about the achievement.

We are making considerations including the option of recommending that the paper be retracted, Ryoji Noyori, who jointly won the Nobel Prize for chemistry in 2001, told a press briefing in Tokyo, according to AFP.

On Friday, Japanese media reported that Haruko Obokata, who published the findings in January, agreed that the research should be pulled back. A joint statement signed by the group of researchers from RIKEN, including Obokata, said the three were considering a possible retraction.

The credibility of the papers have been brought into question, and from the perspective of research ethics, RIKEN is considering the possibility of retracting the two papers published in Nature, the statement said.

See the rest here:
Controversy Around Stem Cell Discovery May Lead To Retraction

Posted in Stem Cells | Comments Off on Controversy Around Stem Cell Discovery May Lead To Retraction

Japan institute admits it may retract 'game-changing' cell study

Posted: March 14, 2014 at 10:45 pm

AFP Japan institute admits it may retract 'game-changing' cell study

Tokyo (AFP) - A Japanese research institute said Friday that a study which promised a revolutionary way to create stem cells should be quashed after claims its data was faulty, dealing a huge blow to what was touted as a game-changing discovery.

Riken institute head, Ryoji Noyori, who jointly won the Nobel Prize for chemistry in 2001, also heaped criticism on lead researcher Haruko Obokata for her "sloppiness" and warned the controversy could shake the public's faith in research.

The findings, published by 30-year-old Obokata along with other Japanese researchers and a US-based scientist in the January edition of British journal "Nature", outlined a relatively simple way to grow transplant tissue in the lab.

But it faced hard questions as the respected institute, which sponsored the study, launched an inquiry last month over the credibility of its data used in the explosive findings.

Among key concerns was that researchers used erroneous images -- crucial to supporting the study -- which resembled those used in Obokata's doctoral dissertation in 2011.

"I apologise that the papers which Riken researchers recently announced in Nature caused an incident that could hurt the credibility of the scientific community," Noyori told a press briefing.

"This immature researcher handled and collected enormous amounts of research data, and handled it with sloppiness... This must never happen."

Riken did not offer an opinion on whether the results of the study were valid, citing a continuing probe. But the institute itself cannot unilaterally retract the paper.

"I have judged that what is most important was for the paper to be swiftly retracted and to conduct the research again. I have suggested that to the authors," said Masatoshi Takeichi, director of Riken's Centre for Developmental Biology.

The rest is here:
Japan institute admits it may retract 'game-changing' cell study

Posted in Stem Cells | Comments Off on Japan institute admits it may retract 'game-changing' cell study

Cancer stem cells destroyed with cryoablation and nanoparticle-encapsulated anticancer drug

Posted: March 14, 2014 at 10:45 pm

Combining nanodrug-based chemotherapy and cryoablation provides an effective strategy to eliminate cancer stem-like cells (CSCs) -- the root of cancer resistance and metastasis, which will help to improve the safety and efficacy of treating malignancies that are refractory to conventional therapies.

Cryoablation (also called cryosurgery or cryotherapy) is an energy-based, minimally invasive surgical technique that has been investigated to treat a variety of diseases including cancer, which is done by freezing the diseased tissue to subzero temperature to induce irreversible damage. It is particularly attractive for fighting against breast cancer due to its excellent cosmetic outcome to preserve the organ with unnoticeable scar formation on skin. However, cryoablation alone has limited effectiveness on eradicating cancer stem-like cells (CSCs), which may lead to cancer recurrence and/or metastasis post operation. A team of researchers from the Department of Biomedical Engineering and Comprehensive Cancer Center at The Ohio State University introduced an innovative strategy by combining cryoablation with nanoparticle-medicated chemotherapy and demonstrated that the combined therapy can significantly augment the destruction of CSCs, resulting in eliminating nearly all CSCs. This technology provides a new approach to overcome drug resistance of CSCs and improve the safety and efficacy of cancer cryoablation.

"This novel combined therapy of cryoablation and nanodrug is a significant step forward in improving the safety and efficacy of fighting against cancer. Our study provides the first account of minimizing cancer recurrence by destroying the cancer stem-like cells in the field of cryoablation for cancer treatment." said Xiaoming He, Ph.D., of The Ohio State University and senior author of this paper. "It is valuable to facilitate the clinical applications of cryoablation by eliminating the root of cancer resistance -- the cancer stem-like cells."

"The nanoparticles used in this study were optimized for effective drug delivery." said Wei Rao, Ph.D., the lead author of the paper. According to the researchers, an optimized size of the nanodrug facilitates its uptake by cancer cells via endocytosis. A positively charged nanodrug has high electrostatic affinity to the negatively charged cell plasma membrane, which should further facilitate its uptake by cancer cells. Moreover, materials on the nanoparticles have high affinity to CD44 that is one of the common protein complexes overexpressed on cancer stem-like cells. Therefore, the use of nanodrug can help to achieve much-enhanced bioavailability of anticancer drug to cancer stem-like cells compared to conventional chemotherapy using free drug. This particularly attractive feature meets the demand of targeted delivery and therapy and could minimize the drug systemic toxicity. Its combination with cryoablation can significantly augment cryoinjury to ensure complete destruction of all cancer stem-like cells.

Currently, research on the combined therapy of cryoablation and nanodrug showed promising results using 3D mammosphere model at the microscale. Future research will focus more on in vivo studies to monitor tumor relapse after the combined treatment and further translate this technology into the clinic. Although more research is required to ascertain its safety and efficacy, this study provides a novel strategy of combining cryoablation and nanodrug that demonstrates great potential to eliminate cancer from its root -- the cancer stem-like cells.

Story Source:

The above story is based on materials provided by World Scientific. Note: Materials may be edited for content and length.

View original post here:
Cancer stem cells destroyed with cryoablation and nanoparticle-encapsulated anticancer drug

Posted in Stem Cells | Comments Off on Cancer stem cells destroyed with cryoablation and nanoparticle-encapsulated anticancer drug

Sweden Medical Forum, part 13 – Ms. Kristina Runeberg, Cellectis – Video

Posted: March 14, 2014 at 10:45 pm


Sweden Medical Forum, part 13 - Ms. Kristina Runeberg, Cellectis
Ms. Kristina Runeberg, Cellectis AB "Industrial platform for scale-up and differentiation of human pluripotent stem cells for Regerative Medicine" Find addit...

By: C0Orinir

View post:
Sweden Medical Forum, part 13 - Ms. Kristina Runeberg, Cellectis - Video

Posted in Regenerative Medicine | Comments Off on Sweden Medical Forum, part 13 – Ms. Kristina Runeberg, Cellectis – Video

FDA's Regulation of Regenerative Medicine including Stem Cell Treatments, Tissue Engineering, Etc.

Posted: March 14, 2014 at 10:45 pm

Course Description: Regenerative medicine focuses on harnessing the power of ones own stem cells and regenerative capabilities to restore function to damaged cells, tissues and organs. In April 2006, the U.S. Food and Drug Administrations (FDA) implemented regulations governing the use of human cells, tissues, and cellular and tissue-based products (HCT/Ps) in humans including bone, ligament, skin, dura mater, stem cells, cartilage cells, and various other cellular and tissue-based products. Currently, there is an ongoing debate in the industry on how such therapies should be regulated by FDA or under the practice of medicine, under federal law or state law, and as drugs or simply biologics.

This 2-day interactive seminar on FDA regulations of regenerative medicine will cover:

-How FDA is currently regulating regenerative therapies and products intended for both human and veterinary use. -The distinction being made between human regenerative products and their regulation as drugs, biologics, devices, and combination products. -The New Drug Application (NDA) and the Biologic License Application (BLA) review and approval processes including a discussion of available options, application components, relevant meetings, timing, costs and approval requirements. -The option for obtaining designation and approval as Orphan Drug Product. -Designing and conducting appropriate clinical trials to support the approval of regenerative therapies. -FDAs regulation of some regenerative medicine products and accessories as Medical Devices. -The Current Good Manufacturing Practices (cGMPs) and Good Laboratory Practices (GLPs) being applied by FDA to human regenerative products. -The labeling and marketing of regenerative products and therapies. -The potential for enforcement action and recommendations for mitigating that risk. -The current regulation of veterinary cellular treatments including autologous, allogeneic and xenogeneic cellular products in the United States.

Learning Objectives: Participants who attend this course on FDA regulation of regenerative medicines will leave with a comprehensive understanding of:

-How FDA regulates regenerative treatments and therapies? -The HCT/P Criteria and Minimal Manipulation Standard. -The Drug and Biological Approval Process. -Regenerative Products as Medical Devices. -How to Design Appropriate Clinical Trials? -Applicable cGMPs and cGLPs. -Marketing Exclusivity and Patent Restoration. -Product Labeling, Marketing and Advertising. -FDA and other Federal Agency Enforcement Action. -The Regulation of Veterinary Regenerative Medicine. -The New Animal Drug Application (NADA) Process. -Veterinary User Fees and Waivers.

Who will benefit: This course is designed for professionals in stem cell, biotech, pharmaceutical and animal drug companies, veterinary hospitals and clinics. The following personnel will find this session valuable:

-Senior quality managers -Quality professionals -Regulatory professionals -Compliance professionals -Production supervisors -Manufacturing engineers -Production engineers -Design engineers -Labelers and Private Labelers -Contract Manufacturers -Importers and Custom Agents -U.S. Agents of Foreign Corporations -Process owners -Quality engineers -Quality auditors -Document control specialists -Record retention specialists -Medical affairs -Legal Professionals -Financial Advisors and Institutional Investors -Consultants, Inspectors and cGMP Experts

See the original post:
FDA's Regulation of Regenerative Medicine including Stem Cell Treatments, Tissue Engineering, Etc.

Posted in Regenerative Medicine | Comments Off on FDA's Regulation of Regenerative Medicine including Stem Cell Treatments, Tissue Engineering, Etc.

New cell line should accelerate embryonic stem cell research

Posted: March 14, 2014 at 10:40 pm

University of Washington researchers have created a line of human embryonic stem cells with the ability to develop into a far broader range of tissues than most existing cell lines.

"These cells will allow us to gain a much greater understanding of normal embryonic development and have the real potential for use in developing ways to grow new tissues and organs for transplantation," said Carol Ware, a professor of comparative medicine. She is the lead author of a paper describing the new cell line.

The findings are reported in the March 10 issue of the journal Proceedings of the National Academy of Sciences. The cells, called nave embryonic stem cells, normally appear at the earliest stages of embryonic development. They retain the ability to turn into any of all the different types of cells of the human body -- a capacity called "pluripotency."

Researchers had been able to develop nave cells using mouse embryonic stem cells, but to create naive human embryonic stem cells has required inserting a set of genes that force the cells to behave like naive cells.

While these transgenic cells are valuable research tools, the presence of artificially introduced genes meant the cells will not develop as normal embryonic cells would nor could they be safely used to create tissues and organs for transplantation.

In an article, Ware and her colleagues from the UW Institute for Stem Cell and Regenerative Medicine describe how they successfully created a line of nave human embryonic stem cells without introducing an artificial set of genes.

They first took embryonic stem cells that are slightly more developed, called primed stem cells, and grew them in a medium that contained factors that switched them back -- or "reverse toggled" them -- to the nave state. They then used the reverse toggled cells to develop a culture medium that would keep them in the nave state and create a stable cell line for study and research.

While the "reverse toggled" cells are much easier to create and will prove valuable research tools, Ware said, the cells that were directly derived from embryos are the more important advance because they are more likely to behave, grow and develop as embryonic cells do in nature.

The new cell line is called Elf1: "El" for the Ellison Foundation, a major supporter of the lab's work; "f" for female, the sex of the stem cell; and "1" for first.

Story Source:

Read this article:
New cell line should accelerate embryonic stem cell research

Posted in Cell Medicine | Comments Off on New cell line should accelerate embryonic stem cell research